

# Lisocabtagene maraleucel for treating relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (terminated appraisal)

Technology appraisal guidance

Published: 10 July 2024

[www.nice.org.uk/guidance/ta987](https://www.nice.org.uk/guidance/ta987)

# Contents

Advice.....	3
Information.....	3

## Advice

NICE is unable to make a recommendation about the use in the NHS of lisocabtagene maraleucel for treating relapsed or refractory aggressive B-cell non-Hodgkin lymphoma in adults. This is because Celgene has confirmed that it does not intend to make an evidence submission for the appraisal. Celgene considers that there is unlikely to be enough evidence that the technology is a cost-effective use of NHS resources in this population.

## Information

If NHS organisations wish to consider lisocabtagene maraleucel for this indication, they should follow the advice on rational local decision making in the [NHS Constitution for England](#) and the [NHS Commissioning Board and Clinical Commissioning Groups \(Responsibilities and Standing Rules\) Regulations 2012](#). This outlines the approach that should be taken when there is no NICE guidance.

NICE will review the position if the company decides that it wants to make an evidence submission.

ISBN: 978-1-4731-6209-9